Dermatologists spend less time face-to-face with Asian patients with psoriasis compared with patients of other races and ethnicities, despite Asian patients frequently experiencing more severe cases of psoriasis.
Asian patients with psoriasis have shorter visit durations with dermatologists than do patients of other races and ethnicities, according to a study published in JAMA Dermatology.
The difference in visit duration by race and ethnicity suggests potential disparities in care, although reasons for this difference are unclear.
The authors suggest that dermatologists have an obligation to provide each patient adequate time to address their concerns, develop strong communication, and build trust. Ineffective physician-patient communication can result in poor treatment adherence, comprehension, satisfaction, and outcomes for the patient.
Researchers performed a cross-sectional study to evaluate the association between a patient’s race and ethnicity and visit duration for psoriasis treatment with a dermatologist.
Data were collected from the National Ambulatory Medical Care Survey from 2010 through 2016 and analyzed in early 2022. In their analyses, researchers adjusted for age, sex, type of visit, visit complexity, insurance status, psoriasis severity on the basis of systemic psoriasis treatment or phototherapy, and complex topical regimen. Race and ethnicity were self-reported by patients.
Researchers identified a weighted estimate of 4,201,745 patient visits for psoriasis (95% CI, 3,688,629-4,714,862).
For demographic characteristics, a significant difference in age was found across the race/ethnicity groups (37.2 [95% CI, 32.0-42.4] years for Asian patients; 44.7 [95% CI, 33.4-56.0] years for Hispanic patients; 33.3 [95% CI, 16.9-49.7] years for Black patients; 54.8 [95% CI, 51.6-58.0] years for White patients; P = .001).
There was also a significant difference in the proportion receiving a complex topical regimen among groups (11.8% among Asian patients, 1.5% among Black patients, and 1.1% among White patients; P = .03).
Mean duration of visits was 9.2 minutes with Asian patients (95% CI, 4.4-14.1), 15.7 minutes with Hispanic or Latino patients (95% CI, 14.2-17.3), 20.7 minutes with non-Hispanic Black patients (95% CI, 14.5-26.9), and 15.4 minutes with non-Hispanic White patients (95% CI, 13.5-17.3).
Visits with Asian patients were found to have a 39.9% shorter mean duration compared with visits with White patients (β coefficient, −5.747 [95% CI, −11.026 to −0.469]; P = .03) and a 40.6% shorter mean duration compared with visits with non-Asian patients as a single group (β coefficient,−5.908 [95% CI, −11.147 to −0.669]; P = .03).
These findings suggest that Asian patients with psoriasis receive significantly less face-to-face time with a dermatologist compared with patients of other races and ethnicities, despite Asian patients tending to present with more severe psoriasis.
However, the etiology of these differences remains unclear, indicating a need for further research. The authors suggest that factors including unconscious bias, cultural differences in communication, or residual confounding might be responsible for the differences observed in these findings.
The authors encourage dermatologists to allow sufficient time to develop strong physician-patient communication regardless of patient background.
The study had limitations. Visit duration was self-reported by the physician or their staff—a method that has been studied in other fields, but formal validation studies are pending.
Researchers imputed missing data on race and ethnicity. They note that it is possible that patients who did not report race and ethnicity may have different characteristics affecting visit duration compared with those who did report this information.
Reference
Wu KK, Armstrong AW. Differences in face-to-face time spent with a dermatologist among patients with psoriasis based on race and ethnicity. JAMA Dermatol. Published online August 3, 2022. doi:10.1001/jamadermatol.2022.2426.
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Goal Achievement in T1D Management Boosts Self-Efficacy, Self-Care Among Emerging Adults
May 9th 2024Findings from the FAMS-T1D study demonstrate that structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults who have type 1 diabetes (T1D).
Read More
Medication Adherence Star Ratings Measures, Health Care Resource Utilization, and Cost
May 9th 2024For patients prescribed diabetes, hypertension, and hyperlipidemia medications, nonadherence to CMS Star Ratings quality measures of medication adherence was associated with increased health care resource utilization and costs.
Read More